Cipla Ltd Q1 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/efcvcf20u1yv8gr1i4wtq35b.pdf

Key Takeaways


One-India: The Distribution Reset

Vohra: "our track record, unfortunately, is not as stellar as we had wanted it to be. But we are part of every process that runs in India in terms of the branded markets, et cetera."

U.S. Business: Record Quarter, Peptide Promise

Vohra: "U.S. business quarterly run rate to be somewhere close to the $235 million to $240 million mark going forward. So we might have seen a little bit of the Lanreotide end up billing in this quarter."

Goa & The Regulatory Gate

Vohra: "I think the FDA will come to its conclusion by end of September. That's the time that we hope to hear from them further."

Margins: Strong Start, No Upgrade

Adukia: "Tender business will pick up in the next 3 quarters. So there will be dilution to overall gross margin in that sense. In Q3, when there's respiratory, at that time, they can be similar margin to Q1, but that's broadly what the trend would be."

Capital Allocation & The Innovation Question

Vohra: "I don't believe that there will be a market where these products can be launched in this year. That's just my opinion as of now."

Rest-of-World & Segments


Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA margin24.5% to 25.5% band; no revision despite Q1 beatFY25 full year
U.S. sustainable quarterly run rate$235 mn to $240 mnGoing forward
R&D expense5% to 6% of sales; max ~6.5% in any quarterFY25 full year
Goa FDA conclusionFDA expected to reach its conclusionBy end-September 2024
Generic Advair filingFiling with 6-month stability data; launch potential Q4 FY25 or H1 next calendar year, conditional on GoaFile Dec/Jan; launch Q4 FY25 at best
Peptide launches (3 expected)Real launches start Q3/Q4; 2 by year-end, 1 next year, 1 more in FY25 or FY26Q3/Q4 FY25 onward
Capex run rateRising to INR1,500–1,800 crores from INR1,000–1,200 croresNear-term
India branded prescriptionRecover from momentary softnessOngoing
One-India trade genericsBack on growth trajectory post-transitionQ2 FY25 onward

Key Metrics

MetricQ1 FY25
Revenue₹6,694 cr, +7% YoY (ex-QCIL)
EBITDA margin (ex-other income)25.6%, +154 bps YoY
EBITDA growth+14% YoY and +30% QoQ (ex-QCIL)
Gross margin after material costs67.2%, +226 bps YoY
Profit after tax₹1,178 cr, 17.6% of sales, effective tax rate 27%
R&D expenses₹353 cr, 5.3% of revenue, +1% vs last year
Cash and equivalents~₹9,000 cr
Net debt₹547 cr (lease liability and working capital)
North America quarterly revenue$250 mn, all-time high, +13% YoY
North America sustainable quarterly run rate$235 mn to $240 mn (per management)
Branded prescription business growth+10% YoY
Chronic share (IQVIA MAT June '24)61.5%, +106 bps YoY
South Africa growth (local currency)+19% YoY
South Africa private market secondary growth7.8% vs market growth of 1.7%
Consumer Health franchise growth+3% YoY
Consumer Health operating profitability15% to 16%
Albuterol market share17%, gained 4% in the quarter (IQVIA week ended 21 June 2024)
Lanreotide 505(b)(2) market share20%, maintained during the quarter
U.S. portfolio price erosion (YoY)~10%
U.S. portfolio price erosion (QoQ)~5% to 6%
MR base~8,500, increased to close to ~10,000 in Q1 FY25
Capex run rate₹1,000 cr to ₹1,200 cr, expected to rise to ₹1,500 cr to ₹1,800 cr
Growth capex share~70% of total capex